Assessment of Patient-Reported Outcome of Patients With Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia and Treated With Tamsulosin HCl in Korea

Hyuk Soo Chang, Choal Hee Park, Dae Kyung Kim, Jong Kwan Park, Sung Joon Hong, Byungha Chung, Jeong Gu Lee, Choung Soo Kim, Kyu Sung Lee, Joon Chul Kim

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Objectives: To evaluate the effect of tamsulosin 0.2 mg once daily in treatment of patients with benign prostatic hyperplasia (BPH) using the new subjective assessment of patient-reported outcomes and the lower urinary tract symptoms (LUTS) outcome score (LOS). Methods: Of 370 patients from 9 urology outpatient clinics, 299 finished this study. Tamsulosin 0.2 mg once daily was administered orally in a nonblind design for a 12-week period. The primary endpoint of this study was to evaluate the effect of tamsulosin with new assessing parameters; the most bothersome symptoms, BPH K1-short form and LOS. The secondary endpoint was to evaluate the effect of tamsulosin with conventional parameters, International Prostate Symptom Score (IPSS), maximum flow rate (Qmax.), and postvoiding residual urine volume. Results: A total of 189 (63.2%) of 299 patients responded that their most bothersome symptom had been improved at 12 weeks after study. All 9 items in BPH K1-short form showed statistically significant improvement (P <.05). Overall, 20 (6.7%) patients met criteria for cured, 246 (82.3%) for improved, and 33 (11.0%) for failed. Statistically significant improvements were observed in IPSS, Qmax., and postvoiding residual urine volume (P <.05). Conclusions: Tamsulosin 0.2 mg once daily may be an effective treatment, subjectively and objectively in patients with BPH. To evaluate the effect of the treatment in patients with BPH, it may be more effective to use the subjective quality of life questionnaire and the subjective-objective data integrated LOS than the currently used IPSS and Qmax..

Original languageEnglish
Pages (from-to)1156-1161
Number of pages6
JournalUrology
Volume75
Issue number5
DOIs
Publication statusPublished - 2010 May 1

Fingerprint

tamsulosin
Lower Urinary Tract Symptoms
Prostatic Hyperplasia
Korea
Prostate
Residual Volume
Urine
Urology
Ambulatory Care Facilities
Patient Reported Outcome Measures
Therapeutics
Quality of Life

All Science Journal Classification (ASJC) codes

  • Urology

Cite this

Chang, Hyuk Soo ; Park, Choal Hee ; Kim, Dae Kyung ; Park, Jong Kwan ; Hong, Sung Joon ; Chung, Byungha ; Lee, Jeong Gu ; Kim, Choung Soo ; Lee, Kyu Sung ; Kim, Joon Chul. / Assessment of Patient-Reported Outcome of Patients With Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia and Treated With Tamsulosin HCl in Korea. In: Urology. 2010 ; Vol. 75, No. 5. pp. 1156-1161.
@article{428ad59954a24c10b3376e71230214a7,
title = "Assessment of Patient-Reported Outcome of Patients With Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia and Treated With Tamsulosin HCl in Korea",
abstract = "Objectives: To evaluate the effect of tamsulosin 0.2 mg once daily in treatment of patients with benign prostatic hyperplasia (BPH) using the new subjective assessment of patient-reported outcomes and the lower urinary tract symptoms (LUTS) outcome score (LOS). Methods: Of 370 patients from 9 urology outpatient clinics, 299 finished this study. Tamsulosin 0.2 mg once daily was administered orally in a nonblind design for a 12-week period. The primary endpoint of this study was to evaluate the effect of tamsulosin with new assessing parameters; the most bothersome symptoms, BPH K1-short form and LOS. The secondary endpoint was to evaluate the effect of tamsulosin with conventional parameters, International Prostate Symptom Score (IPSS), maximum flow rate (Qmax.), and postvoiding residual urine volume. Results: A total of 189 (63.2{\%}) of 299 patients responded that their most bothersome symptom had been improved at 12 weeks after study. All 9 items in BPH K1-short form showed statistically significant improvement (P <.05). Overall, 20 (6.7{\%}) patients met criteria for cured, 246 (82.3{\%}) for improved, and 33 (11.0{\%}) for failed. Statistically significant improvements were observed in IPSS, Qmax., and postvoiding residual urine volume (P <.05). Conclusions: Tamsulosin 0.2 mg once daily may be an effective treatment, subjectively and objectively in patients with BPH. To evaluate the effect of the treatment in patients with BPH, it may be more effective to use the subjective quality of life questionnaire and the subjective-objective data integrated LOS than the currently used IPSS and Qmax..",
author = "Chang, {Hyuk Soo} and Park, {Choal Hee} and Kim, {Dae Kyung} and Park, {Jong Kwan} and Hong, {Sung Joon} and Byungha Chung and Lee, {Jeong Gu} and Kim, {Choung Soo} and Lee, {Kyu Sung} and Kim, {Joon Chul}",
year = "2010",
month = "5",
day = "1",
doi = "10.1016/j.urology.2009.09.010",
language = "English",
volume = "75",
pages = "1156--1161",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "5",

}

Assessment of Patient-Reported Outcome of Patients With Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia and Treated With Tamsulosin HCl in Korea. / Chang, Hyuk Soo; Park, Choal Hee; Kim, Dae Kyung; Park, Jong Kwan; Hong, Sung Joon; Chung, Byungha; Lee, Jeong Gu; Kim, Choung Soo; Lee, Kyu Sung; Kim, Joon Chul.

In: Urology, Vol. 75, No. 5, 01.05.2010, p. 1156-1161.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Assessment of Patient-Reported Outcome of Patients With Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia and Treated With Tamsulosin HCl in Korea

AU - Chang, Hyuk Soo

AU - Park, Choal Hee

AU - Kim, Dae Kyung

AU - Park, Jong Kwan

AU - Hong, Sung Joon

AU - Chung, Byungha

AU - Lee, Jeong Gu

AU - Kim, Choung Soo

AU - Lee, Kyu Sung

AU - Kim, Joon Chul

PY - 2010/5/1

Y1 - 2010/5/1

N2 - Objectives: To evaluate the effect of tamsulosin 0.2 mg once daily in treatment of patients with benign prostatic hyperplasia (BPH) using the new subjective assessment of patient-reported outcomes and the lower urinary tract symptoms (LUTS) outcome score (LOS). Methods: Of 370 patients from 9 urology outpatient clinics, 299 finished this study. Tamsulosin 0.2 mg once daily was administered orally in a nonblind design for a 12-week period. The primary endpoint of this study was to evaluate the effect of tamsulosin with new assessing parameters; the most bothersome symptoms, BPH K1-short form and LOS. The secondary endpoint was to evaluate the effect of tamsulosin with conventional parameters, International Prostate Symptom Score (IPSS), maximum flow rate (Qmax.), and postvoiding residual urine volume. Results: A total of 189 (63.2%) of 299 patients responded that their most bothersome symptom had been improved at 12 weeks after study. All 9 items in BPH K1-short form showed statistically significant improvement (P <.05). Overall, 20 (6.7%) patients met criteria for cured, 246 (82.3%) for improved, and 33 (11.0%) for failed. Statistically significant improvements were observed in IPSS, Qmax., and postvoiding residual urine volume (P <.05). Conclusions: Tamsulosin 0.2 mg once daily may be an effective treatment, subjectively and objectively in patients with BPH. To evaluate the effect of the treatment in patients with BPH, it may be more effective to use the subjective quality of life questionnaire and the subjective-objective data integrated LOS than the currently used IPSS and Qmax..

AB - Objectives: To evaluate the effect of tamsulosin 0.2 mg once daily in treatment of patients with benign prostatic hyperplasia (BPH) using the new subjective assessment of patient-reported outcomes and the lower urinary tract symptoms (LUTS) outcome score (LOS). Methods: Of 370 patients from 9 urology outpatient clinics, 299 finished this study. Tamsulosin 0.2 mg once daily was administered orally in a nonblind design for a 12-week period. The primary endpoint of this study was to evaluate the effect of tamsulosin with new assessing parameters; the most bothersome symptoms, BPH K1-short form and LOS. The secondary endpoint was to evaluate the effect of tamsulosin with conventional parameters, International Prostate Symptom Score (IPSS), maximum flow rate (Qmax.), and postvoiding residual urine volume. Results: A total of 189 (63.2%) of 299 patients responded that their most bothersome symptom had been improved at 12 weeks after study. All 9 items in BPH K1-short form showed statistically significant improvement (P <.05). Overall, 20 (6.7%) patients met criteria for cured, 246 (82.3%) for improved, and 33 (11.0%) for failed. Statistically significant improvements were observed in IPSS, Qmax., and postvoiding residual urine volume (P <.05). Conclusions: Tamsulosin 0.2 mg once daily may be an effective treatment, subjectively and objectively in patients with BPH. To evaluate the effect of the treatment in patients with BPH, it may be more effective to use the subjective quality of life questionnaire and the subjective-objective data integrated LOS than the currently used IPSS and Qmax..

UR - http://www.scopus.com/inward/record.url?scp=77951665401&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951665401&partnerID=8YFLogxK

U2 - 10.1016/j.urology.2009.09.010

DO - 10.1016/j.urology.2009.09.010

M3 - Article

VL - 75

SP - 1156

EP - 1161

JO - Urology

JF - Urology

SN - 0090-4295

IS - 5

ER -